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ABSTRAK
Latar belakang: infeksi HIV mempercepat progresifitas penyakit pada penderita hepatitis C dan menurunkan 
angka keberhasilan terapi Peg-IFN/RBV. Mutasi VHC pada regio NS5A-ISDR/PKR-BD meningkatkan hasil 
luaran yang lebih baik pasien monoinfeksi VHC yang diterapi dengan Peg-IFN/RBV. Polimorfisme SNP IL-28B 
diprediksi memiliki efek terhadap evolusi quasispecies VHC. Akan tetapi, peran mutasi NS5A dan SNP IL-28B 
pada koinfeksi VHC-HIV masih belum jelas. Tujuan dari penelitian ini adalah untuk mengetahui peran mutasi 
VHC NS5A-ISDR/PKR-BD dan polimorfisme SNP IL-28B terhadap keberhasilan terapi Peg-IFN/RBV pada 
koinfeksi VHC-HIV. Metode: studi ini menggunakan desain studi kohort prospektif. Sampel plasma dikumpulkan 
dari 30 pasien koinfeksi VHC-HIV  dan 8 monoinfeksi VHC. Sekuensing nukleotida PCR dilakukan setelah proses 
ekstraksi RNA dan sintesis cDNA. Analisis struktur sekunder dan prediksi fungsi mutasi menggunakan program 
PredictProtein(PP). Hasil: sebanyak 16 pasien koinfeksi VHC-HIV mencapai SVR. Tidak ada pasien monoinfeksi 
yang mencapai SVR. Mutasi nonnetral ≥1 ditemukan pada 24/30 pasien koinfeksi dan lebih sering ditemukan 
pada kelompok SVR (14 pasien). Mutasi nonnetral ≥1 ditemukan bermakna secara statistik terhadap status SVR 
(p<0,05), terlepas dari status koinfeksi ataupun monoinfeksi. Dari 27 pasien koinfeksi yang memiliki gen CC, 
sebanyak 21 pasien memiliki mutasi nonnetral. Struktur yang diduga sebagai binding site didapatkan berbeda 
dibanding konsensus pada kelompok SVR, sedangkan pada kelompok non-SVR struktur tersebut sama dengan 
konsensus. Kesimpulan: mutasi nonnetral ≥1 berhubungan dengan tercapainya SVR pada terapi Peg-IFN/RBV, 
terlepas dari status monoinfeksi atau koinfeksi.
Kata kunci: NS5A-ISDR/PKR-BD, SNP IL-28B, koinfeksi VHC-HIV, mutasi nonnetral, SVR.
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ABSTRACT
Background: HIV infection in HCV-infected patients accelerates disease progression and reduces the 
success rate of Peg-IFN/RBV treatment. HCV mutation in NS5A-ISDR/PKR-BD region improved the outcome 
in HCV monoinfection treated with Peg-IFN/RBV. SNP-IL28B polymorphism is predicted to have an effect on 
HCV quasispecies evolution. However, the role of NS5A mutation and SNP IL-28B in HIV-HCV coinfection is 
still unclear. The aim of the study is to determine the role of HCV NS5A-ISDR/PKR-BD mutation and SNP IL-28 
polymorphism on the successfulness of Peg-IFN/RBV therapy in HCV-HIV coinfection. Methods: prospective cohort 
was performed in this study. Plasma sample were obtained from 30 and 8 patients with HCV-HIV coinfection and 
HCV monoinfection, respectively. PCR nucleotide sequencing was performed after RNA virus extraction and cDNA 
synthesis. Protein secondary structure and prediction of mutation function were analyzed using PredictProtein 
(PP) program. Results: sixteen HCV-HIV coinfected patients and none from eight HCV patients achieved sustained 
virological response (SVR). ≥1 non-neutral mutation was found in 24/30 HCV-HIV coinfection and more frequent in 
SVR group (14 patients). ≥1 non-neutral mutation were found statistically significant for overall SVR achievement 
(p<0.05) in all patients regardless of coinfection or monoinfection status. Of the 27 HCV-HIV coinfected patients 
with CC-gene, 21 subjects had non-neutral mutation. The structure which was expected as NS5A binding site 
structure was different from consensus (wild type) in SVR group, while the structure was similar to consensus in 
non-SVR group. Conclusion: having ≥1 non-neutral mutation was associated with SVR achievement in Peg-IFN/
RBV therapy, regardless of monoinfection and coinfection status.
Keywords: NS5A-ISDR/PKR-BD, SNP IL-28B, HCV-HIV coinfection, non-neutral mutation, SVR.
INTRODUCTION
Hepatitis C virus (HCV) infection is one of 
the leading causes of death in HIV patients and 
HIV infection in hepatitis C patients increases 
the risk of  cirrhosis, hepatocellular carcinoma 
(HCC) and death.1,2 In the United States, 
approximately 25% of HIV-infected patients also 
had HCV coinfection.3 In Cipto Mangunkusumo 
National General Hospital, around 67.9% 
of 3,613 new cases of HIV-infected patients 
had positive anti-HCV serology.4 Pegylated 
interferon and ribavirin (Peg-IFN/RBV) is one 
of treatment options for chronic hepatitis C in 
patients with HCV-HIV coinfection. Several 
studies have been conducted to determine the 
outcome predictor of hepatitis C patients treated 
with Peg-IFN/RBV.5-7
HCV mutation in NS5A IFN sensitivity 
determining region (ISDR) and protein kinase 
R-binding domain (PKR-BD) was suspected 
to be a predictor of Peg-IFN/RBV treatment 
response. El-Shamy study8 showed that 71% 
patients who had ≥1 mutation in NS55A ISDR 
region achieved SVR. De Rueda study9 showed 
that having ≥4 mutation in NS55A PKR-BD 
region was associated with SVR (p = 0.001) 
in HCV patients who received Peg-IFN/RBV 
combination therapy. However, different results 
were reported from two Western studies. 
Zeuzem, et al10 reported that there was no 
correlation between the number of amino acid 
mutations in ISDR region and the decreased 
HCV-RNA levels. Hofgartner11 also reported that 
amino acid substitution in ISDR region was not 
related to interferon resistance in HCV genotype 
1a patients.
The prediction of mutation function of 
a protein is influenced by three factors, i.e. 
structure, sequence and annotation.12 Amino 
acid mutations could not be observed only by 
looking at the number of mutations, but the role 
of the mutation to its function also needs to be 
observed. Non-synonymous mutation is defined 
as a substitution of nucleotide which causes 
change in the amino acid sequences, while non-
neutral mutation is defined as a mutation which 
causes change in the function.13 In additon to 
NS5A mutation, single nucleotide polymorphism 
(SNP) IL-28B on human chromosome 19 can 
also predict the response of therapy on HCV 
infection, but the mechanism is still not clearly 
known.14 Therefore, this study was conducted 
to determine the role of HCV RNA mutations 
(particularly non-neutral mutations) in NS5A-
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ISDR/PKR-BD region and host SNP IL-28B in 
the successfulness of hepatitis C therapy using 
combination of Peg-IFN/RBV in HCV-HIV 
coinfection.
METHODS
Study Design and Patient Selection
A prospective cohort design was used in 
this study. HCV-HIV coinfected and HCV 
monoinfected patients were recruited from 
HIV Clinic and Hepatology Clinic in Cipto 
Mangunkusumo National General Hospital, 
respectively, from July 2015 to July 2017. 
HCV-HIV coinfected patients with CD4 count 
bertween 200-350 cells/μL for patients who 
were on antriretroviral therapy (ART) or CD4 
count above 350 cells/mL for patients who were 
not on ART liver fibrorsis >F1 were included 
in this study. All patients who were willing 
to participate in this study were asked to sign 
informed consent form. Strict inclusion and 
exclusion criteria were applied in order to avoid 
bias and to control confounding variables in this 
study. The minimum sample size was calculated 
by using hypothetical test of differences between 
two proportions.
Viral RNA Extraction and cDNA Synthesis
Viral RNA was extracted from 200 µL 
plasma samples using a High Pure viral nucleic 
acid kit. As many as 3 µL of RNA template 
underwent reverse transcription-polymerase 
chain reaction (RT-PCR) to produce cDNA 
by using Tetro cDNA synthesis kit. PCR for 
NS5A region of genotype 1b HCV used Taq 
Polymerase DNA and primer pair of 5A-1b-1 
(sense) 5’-ATTCCAGGTCGGGCTCAA-3’ and 
5A-1-2R (antisense) 5’-ACGGTAGACCAAGA 
CCCGTC-3’ for the first stage PCR. Three 
microliters from the first stage PCR reaction 
were used for second stage PCR (nested-PCR) 
by using primer  pair of  5A-1b-3 (sense) 
5’-ACTTCCATGCTCACCGACCC-3‘ and 
5A-1-4R primers (antisense) 5’-AGAGGGGG 
CATGGAGGAGTA -3’.15 These primer pairs 
were also used as the sequential primer for 
genotype 1b HCV.
The primer pairs used in the PCR process 
and sequencing of NS5A region genotypes 1a, 
3 and 4 HCV were primer pairs specifically 
designed using Primer3Plus program based on 
30 strands of HCV whole genome from various 
countries. Three microliters from the first stage 
PCR reaction were used for the second stage of 
PCR (nested-PCR). These primer pairs were also 
used as the sequential primer for genotypes 1a, 
3, 4 and 6 HCV. The amplification results were 
analyzed by electrophoresis using 1.5% agarose 
gel (in 1x TAE) with SYBR® Safe DNA Gel 
Stain dye and documented using ultra violet 
transilluminator.
Nucleotide Sequencing
The purified PCR product was sequenced 
by using automatic sequencer ABI Prism 3730 
XL genetic analyzer DNA sequencer and dye 
terminator sequencing kit. The electrophoregram 
of each sequence was examined and modified by 
using Macimum Composite Likelihood Method 
(MEGA) software version 7.0.
Secondary Structure Analysis and Mutation 
Function Prediction
The analysis of secondary structure of HCV 
NS5A-ISDR/PKR-BD protein sequence was 
performed by using Predict Protein (PP) program. 
Screening for non-acceptable polymorphisms 2 
(SNAP2) is a service which is provided by PP to 
predict the effects of amino acid substitution in 
the change of  protein function. The accuracy of 
SNAP is 77% in detecting 80% of non-neutral 
mutation.
Data Analysis
Dichotomous data was presented in 
proportions, while numerical data was presented 
in mean with standard deviation or median with 
the interquartile range. Bivariate analysis of 
categorical data was carried out using Chi Square 
and numerical data using unpaired T test or 
Mann-Whitney analysis. The p value <0.05 was 
considered statistically significant. Statistical 
analysis was performed by using SPSS version 
23.00.
Research Ethics
This study has been approved by the Medical 
Research Ethics Committee of Faculty of 
Medicine, Universitas Indonesia with a reference 
number 725/UN2.FI/ETIK/2015.
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RESULTS
Thirty patients with HCV-HIV coinfection 
and eight patients with HCV monoinfection were 
included and analyzed in this study.
Genotype 1a was the most common genotype 
found in the HCV-HIV coinfection group, 
followed by genotype 3 and 4. No genotype 1b 
was found in this group. As many as 90% of HCV-
HIV coinfected patients had CC gene, while 75% 
of HCV monoinfected patients had non-CC gene. 
HCV NS5A-ISDR/PKR-BD mutation was not 
significantly different between coinfection and 
monoinfection group. However, ≥1 non-neutral 
mutation was statistically significant between 
HCV-HIV coinfected and HCV monoinfected 
patients (p=0.049). The demographic, laboratory 
and HCV NS5A mutation characteristics were 
shown in Table 1.
HCV NS5A-ISDR/PKR-BD Mutation and SVR
In this study, the association between neutral, 
non-neutral, synonymous, non-synonymous 
mutation and SVR in HCV-HIV coinfected 
Table 1. Demographic, laboratory and mutation characteristics
Variables HCV-HIV coinfection (n = 30) HCV monoinfection (n = 8)
Demographic data
Gender, n (%)
 - Male 29 (96.7) 2 (25)
 - Female 1 (3.3) 6 (75)
Age (years)a 36.43 (3.4) 51.13 (10.02)
Cirrhosis, n (%)
 - Yes 15 (50) 0 (0)
 - No 15 (50) 8 (100)
Laboratory data
CD4 (cells/µL)b 495 (219-886) -
Viral load (log IU/mL)b 1.47 x 106 (3.49 x 105–2.17 x 107) 2.53x106 (1.73x104–1.39 x 107)
Genotype, n (%)
1a 23 (76.7) 0 (0)
1b 0 (0) 8 (100)
3 4 (13,3) 0 (0)
4 3 (10) 0 (0)
IL28B gene variation, n (%)
 - CC 27 (90) 2 (25)
 - Non-CC 3 (10) 6 (75)
SVR status, n(%)
 - SVR 16 (53.3) 0 (0)
 - Non SVR 14 (46.7) 8 (100)
Mutation characteristicsb
 - Number of neutral mutation 5 (2–9) 4 (2–6)
 - Number of non-neutral mutation 1 (0–11) 0 (0–3)
 - Number of synonymous mutation 3 (1–8) 2 (0–3)
 - Number of non-synonymous mutation 3 (0–12) 3 (2–7)
 - Total mutation in all categories 6 (3–20) 5 (3–9)
Amino acid substitution, n (%)
 - neutral ≥ 4/ < 4 24 (80%)/ 6 (20%) 4 (50%)/ 4 (50%)
 - non-neutral ≥ 1/ < 1 23 (76.7%)/ 7 (23.3%) 3 (37.5%)/ 5 (62.5%)
 - synonymous ≥ 3/ < 3 19 (63.3%)/ 11 (36.7%) 2 (25%)/ 6 (75%)
 - non-synonymous ≥ 3/ < 3 22 (73.3%)/ 8 (26.7%) 7 (87.5%)/ 1 (12.5%)
a : mean (SD); b : median (minimum - maximum)
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patients was not statistically significant. However, 
in the subanalysis in all patients regardless of 
coinfection or monoinfection status, having ≥1 
non-neutral mutation was associated with higher 
SVR rate (p=0.04). (Table 2) The presence of both 
non-neutral and non-synonynous mutation was 
not associated with SVR achievement in HCV-
HIV coinfected patients. (Table 3)
HCV NS5A-ISDR/PKR-BD Mutation and SNP 
IL-28B
No significant association was found between 
HCV NS5A-ISDR/PKR-BD mutation and 
SNP IL-28B in HCV-HIV coinfected patients. 
However, patients with CC gene have a tendency 
to acquire non-neutral and non-synonymous 
mutation in HCV NS5A region. (Table 4)
Table 2. HCV NS5A-ISDR/PKR-BD mutation and SVR rate
Variables
Coinfection and Monoinfection (n = 38)
Non SVR SVR Total p
NS5A-ISDR/PKR-BD mutation
 - (neutral), ≥ 4 17 (60.7%) 11 (39.3%) 28 (100%) *0.713
 - (neutral), < 4 5 (50%) 5 (50%) 10 (100%) -
NS5A-ISDR/PKR-BD mutation
 - (non-neutral), ≥ 1 12 (46.2%) 14 (53.8%) 26 (100%) *0.040
 - (non-neutral), < 1 10 (83.3%) 2 (16.7%) 12 (100%) -
NS5A-ISDR/PKR-BD mutation
 - (synonymous), ≥ 3 10 (47.6%) 11 (52.4%) 21 (100%) *0.197
 - (synonymous), < 3 12 (70.6%) 5 (29.4%) 17 (100%) -
NS5A-ISDR/PKR-BD mutation
 - (non-synonymous), ≥ 3 19 (65.5%) 10 (34.5%) 29 (100%) *0.128
 - (non-synonymous), < 3 3 (33.3%) 6 (66.7%) 9 (100%) -
* Chi square




Non-SVR (n = 14) SVR (n = 16)
The association between mutations in non-synonymous and non-neutral
Mutation (+) in Non-synonymous with 
Mutation (+) in Non-neutral 8 (47.1%) 9 (52.9%) *0.220
Mutation (+) in Non-synonymous with 
Mutation (-) in Non-neutral 4 (80%) 1 (20%)
Mutation (-) in Non-synonymous with 
Mutation (+) in Non-neutral 1 (16.7%) 5 (83.3%)
Mutation (-) in Non-synonymous with 
Mutation (-) in Non-neutral 1 (50%) 1 (50%)
* Chi square test





Mutation (-) Mutation (+) Mutation (-) Mutation (+)
CC gene 6 (22.2%) 21 (77.8%) *1.000 6 (22.2%) 21 (77.8%) *1.000





Mutation (-) Mutation (+) Mutation (-) Mutation (+)
CC gene 10 (37%) 17 (63%) *1.000 7 (25.9%) 20 (74.1%) *1.000
Non CC gene 1 (33.3%) 2 (66.7%) 1 (33.3%) 2 (66.7%)
* Chi square test
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Protein Secondary Structure and SVR
There is no significant association between 
HCV NS5A mutation and the change of protein 
secondary structure in HCV-HIV coinfected 
patients. In a separate analysis, the change of 
protein secondary structure was not associated 
with SVR achievement (data is not shown).
Binding Site Structure in SVR and Non-SVR 
Groups
In the in-depth analysis, the structure which 
was expected as HCV NS5A binding site 
structure was not different between the wild type 
(consensus) and non-SVR group. Meanwhile, 
this structure was different between SVR group 
and consensus, as shown in Figure 1.
been known to play major roles in poor treatment 
response, which include old age, genotype 1 
HCV, high viral load of HCV, advanced fibrosis 
and non-CC gene.7,18 Old age, non-CC gene and 
genotype 1 HCV might be the cause of no SVR 
in HCV monoinfection group in this study.
In univariate analysis, mutation of HCV 
NS5A-ISDR/PKR-BD region was not statistically 
significant between monoinfection and coinfection 
groups. Meanwhile, there was a tendency of 
increased mutation incidence in the coinfection 
group. To the best of our knowledge, no study 
has reported this finding in HCV-HIV coinfected 
patients. A study reported that increased mutation 
rate of NS5A resistance-associated substitutions 
(RAS) in domain I is more common in HCV-HIV 
coinfected patients than in HCV monoinfected 
patients, however this was associated with 
therapeutic response to daclatasvir.19
It is suspected that the high number of 
mutations in HCV-HIV coinfection was the result 
of increased rate of HCV replication. TGF-β1 
expression in hepatocytes and circulation were 
increased due to HIV infection. TGF-β1 is a 
stimulator for HCV replication, thus increasing 
HCV replication in hepatocytes by 2-3 folds.20,21 
Another mechanism is HIV infection acting 
as inducer of HCV replication in human 
macrophages.22 Elevated rate of HCV replication 
increases the probability of mutation on this RNA 
virus that lack of proofreading ability.23,24
The presence of HCV NS5A-ISDR/PKR-
BD mutation was not statistically significant 
towards the achievement of SVR in this study. 
Of the 30 HCV-HIV coinfected patients, non-
neutral mutation and non-synonymous mutation 
were found in 23 and 22 patients, respectively. 
As many as 17 patients had both mutations. To 
explore the contribution of non-neutral mutation 
in SVR, having ≥1 non-neutral mutations 
was found statistically significant towards the 
achievement of SVR (p<0.05), regardless of the 
coinfection or monoinfection status. There was 
no significant association between non-neutral 
mutation and SVR rate in both groups, however 
HCV-HIV coinfected patients who had non-
neutral mutation tended to have higher SVR rate. 
Therefore, the role of non-synonymous mutation 
is assumed to have less impact in SVR rate if 
Figure 1. Binding site structure of HCV NS5A.
Figure 1A) The comparison between binding site structure of 
HCV NS5A wild type (consensus) and non-SVR group. No 
significant difference between wild type and non-SVR group. 
Figure 1B) The comparison between binding site structure 
of HCV NS5A consensus and SVR group. The binding site 
structures were completely different between the two.
DISCUSSION
The most common HCV genotype in 
HCV-HIV coinfected patients was 1a (76.7%), 
followed by genotype 3 (13.3%) and 4 (10%). 
All HCV monoinfection patients had genotype 
1b. Geographical factors had a major role in the 
spread of HCV genotypes. Genotype 1b is the 
most prevalent genotype found in Indonesia.16 
The change of genotypes distribution in the 
HCV-HIV group in this study might be due to 
HIV route of transmission.17
As many as 53.3% of HCV-HIV coinfected 
patients achieved SVR. None of monoinfected 
patients achieved SVR. Several factors have 
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compared to non-neutral mutation.
NS5A structure in HCV acts as interferon 
antiviral inhibitor.25 Therefore, non-neutral 
mutation of HCV NS5A-ISDR/PKR-BD can 
become advantageous mutation as it is related to 
better outcome in Peg-IFN/RBV therapy.
Non-neutral mutation is known to affect the 
protein structure.14 In this study, there was no 
significant association between the changes of 
HCV NS5A secondary structure in NS5A-ISDR/
PKR-BD region and SVR achievement in the 
coinfection group. This is probably because the 
changes in secondary structure of all NS5A did 
not have any major roles in SVR achievement. In 
the in-depth analysis of NS5A secondary structure 
which was focused on the structure which was 
predicted as binding site, it was found that the 
HCV NS5A binding site structure in HCV-HIV 
coinfected patients who did not achieve SVR was 
not too different from the binding site structure 
according to HCV consensus (the wild type). 
HCV-HIV coinfected patients who achieved SVR 
had a different binding site structure compared to 
the wild type (Figure 1). Therefore, the changes 
of binding site structure associated with ≥1 non-
neutral mutation is expected to play an important 
role in SVR achievement in HCV-HIV coinfected 
patients treated with Peg-IFN/RBV.
The association between SNP IL-28B 
polymorphism and HCV NS5A mutation was 
not statistically significant. However, there was 
a tendency for patients with CC gene to have a 
higher rate of non-neutral and non-synonymous 
mutations. Similar findings were reported by 
Halfon26, i.e. CC gene was associated with SVR 
achievement, particularly in genotype 1 with OR 
of 3.3 (1.58-6.9) and p = 0.03. Khubaib et al27 
also reported similar result, i.e. CC gene was an 
independent predictor of SVR in patients with 
chronic HCV infection.
The antiviral effect of interferon is achieved 
through the activation of IFN cascade. The main 
molecule in IFN pathway is signal transducer 
and activator of transcription 1 (STAT1). This 
Figure 2. The mechanism of non-neutral mutation of HCV NS5A-ISDR/PKR-BD in patiets who were treated with Peg-IFN/RBV 
therapy. The replication process of HCV continues because eukaryotic initiation factor-2 α (eIF-2α) is not phosphorylated. When 
a patient is treated with Peg-IFN/RBV regimen, interferon binds to interferon receptor which then activates protein kinase-R 
(PKR). Activation of PKR leads to phosphorylation of eIF-2α which will inhibit protein synthesis for translation process, so that 
HCV replication stops. Through its NS5A structure, HCV suppresses PKR activation, thus inhibiting phosphorylation of eIF-2α 
and the HCV replication process continues. The non-neutral mutation of NSA-inteferon sensitivity determining region/protein 
kinase R – binding domain (NS5A-ISDR/PKR-BD) ≥ 1 amino acid, particularly in the structure which is considered as binding 
site, reactivates PKR and stops the HCV replication process. Therefore, non-neutral mutation of HCV NS5A-ISDR/PKR-BD is 
associated with better outcome in Peg-IFN/RBV therapy.
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molecule will undergo phosphorylation and 
translocation into nucleus, which then will 
induce the interferon-stimulating gene (ISG).25 
The activity of ISG plays an important role in 
the mechanism where CC gene affects SVR. 
Patients with CC gene are known to have lower 
ISG activity, which indicated that IFN activity is 
not optimal yet, therefore combination therapy 
with Peg-IFN/RBV will increase the response 
of IFN. High ISG levels in patients with non-CC 
gene indicates that IFN activity is optimal and 
therefore provision of interferom-based therapy 
will result in low SVR.28,29
Figure 2 explains the effect of non-neutral 
mutation of HCV NS5A- ISDR/PKR-BD to the 
outcome of Peg-IFN/RBV therapy.
The recommendation for chronic hepatitis 
C therapy has shifted towards Direct Acting 
Antiviral (DAA). The use of DAA in Indonesia 
for hepatitis C therapy is currently facilitated 
by government program and the supply is 
sometimes not sustainable. Therefore, the use of 
interferon-based therapy is still one of the options 
for chronic hepatitis C therapy in Indonesia and 
other countries with low DAA availability.
CONCLUSION
HCV-HIV coinfected patient with CC gene 
and ≥ 1 non-neutral mutation in NS5A-ISDR/
PKR-BD region tends to have better outcome 
with Peg-IFN/RBV therapy.
RECOMMENDATION
A study with larger sample size is 
recommended. This study is also expected to 
become a basis for other researchers to study 
the HCV NS5A mutation as initial predictor for 
response of of DAA therapy .
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